10-Q · May 14, 2026
MeiraGTx reported a significant revenue increase of approximately 382% year-over-year, achieving $75 million in Q4 2025, compared to $21 million in Q4 2024. EPS turned positive at $0.19, a remarkable turnaround from a…
Earnings analysis · 10-Q
MGTX earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
MeiraGTx reported $321.434 million of revenue and $1.71 diluted EPS, compared with $3.691 million of revenue and a $0.48 diluted loss in the prior-year quarter. The increase was driven by $204.643 million of license…
Read full summary
MeiraGTx reported $321.434 million of revenue and $1.71 diluted EPS, compared with $3.691 million of revenue and a $0.48 diluted loss in the prior-year quarter. The increase was driven by $204.643 million of license revenue and $104.906 million of related-party service revenue, but the filing characterizes profitability as primarily non-recurring. Liquidity improved to $145.4 million of cash, cash equivalents and restricted cash, with management estimating funding into the second half of 2028, although the company remains a clinical-stage business with an accumulated deficit of approximately $701.8 million and substantial future financing and development risks.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
Reported figures
- Earnings per share
- $1.71
What stood out
-
Collaboration revenue surged
Revenue was $321.434 million, up from $3.691 million in the prior-year quarter, an increase of approximately $317.743 million or 86.1x. The result was primarily driven by $204.643 million of license revenue and $104.906 million of related-party service revenue.
-
Returned to diluted profitability
Diluted EPS was $1.71 versus a diluted loss of $0.48 in the prior-year quarter, a $2.19 per-share improvement. The filing indicates profitability was primarily attributable to non-recurring transactions.
-
Liquidity runway extended
Cash, cash equivalents and restricted cash totaled $145.4 million at June 30, 2026. Management estimates available resources and identified proceeds will fund operating expenses and capital expenditures into the second half of 2028.
-
Secured additional financing capacity
The company entered into a Royalty Note Purchase Agreement providing for up to $375 million of purchases, including an initial $100 million purchase on June 30, 2026 and a $25 million second purchase on July 17, 2026.
-
Eliminated floating-rate debt
The company repaid all outstanding borrowings and terminated its prior Notes Purchase Agreement on June 30, 2026, leaving no fluctuating-rate debt outstanding at quarter end.
-
Regulatory milestones advancing
Management expects global regulatory filings for bota-vec in 2026, while the AAV2-hAQP1 program could support a BLA filing in mid-2027. AAV-hAQP1 received Breakthrough Therapy Designation in March 2026.
What to watch
-
Non-recurring profit and large deficit
Current-period profitability is not necessarily sustainable: the filing states that profitability was primarily attributable to non-recurring transactions, while accumulated deficit was approximately $701.8 million as of June 30, 2026.
-
Royalty financing encumbers future economics
The Royalty Note Purchase Agreement permits up to $375 million of senior secured notes and requires Revenue Payments equal to 1.95% of global net sales of AAV-AIPL1, AAV-hAQP1 and bota-vec after approval. The obligations are secured by cash, receivables, property, plant and equipment, equity interests and specified product assets.
-
Unhedged foreign-exchange exposure
Management estimates a 10% unfavorable currency movement would create an additional foreign-currency loss of approximately $14.3 million for the six months ended June 30, 2026. The company held no foreign-currency forward contracts as of June 30, 2026.
-
No approved commercial product
The company has no approved products for commercial sale and states it has not completed any clinical development program required for product approval. Regulatory uncertainty remains material for programs including bota-vec and AAV-hAQP1.
-
Clinical development remains cash intensive
The company expects continued significant expenses and operating losses as it advances clinical programs and manufacturing activities, despite reporting $1.71 of diluted EPS in the current quarter.
-
Ongoing equity dilution risk
The company raised $28.2 million through its at-the-market program during the six months ended June 30, 2026 by issuing 3,164,365 ordinary shares, creating potential dilution if additional equity is needed.
Management's outlook
No formal numeric revenue or EPS guidance was provided. Management estimates that cash, receivables, the $25.0 million second Royalty Note purchase, $10.0 million of third-quarter equity proceeds, and the expected $95.0 million Hologen upfront payment and reimbursements will fund operating and capital needs into the second half of 2028. The estimate excludes $135.0 million of potential near-term Lilly milestone consideration.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.